A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007799/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab
in participants with moderate-to-severe plaque psoriasis.
提供机构：
Vivli
创建时间：
2022-03-17
